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We previously have reported that innate immune sen-
sing of tumors in vivo involves type I IFN production by
dendritic cells (DCs), which in turn acts on CD8a+ DCs
to promote endogenous cross-priming of CD8+ T cells
in vivo. Recently, we have identified the cytosolic DNA
sensing pathway involving the molecule STING as the
major upstream mechanism that leads to type I IFN
production and DC activation in the setting of tumor
implantation in vivo. Since most spontaneous T cell
priming against tumors in vivo is suboptimal, ultimately
ineffective, and fails to cause tumor rejection, we rea-
soned that stronger activation of the STING pathway
could have therapeutic efficacy. To test this notion, we
utilized DMXAA (5,6-dimethylxanthenone-4-acetic
acid), a xanthenone derivative recently shown to directly
bind to murine STING. In vitro, DMXAA led to STING
aggregation as assessed by ImageStream cytometry, and
induced phosphorylation of the downstream signaling
proteins TBK1 and IRF3. Functionally, this led to the
production of not only IFN-b, but also IL-6, TNF-a,
and IL-12, as well as upregulated expression of MHCII,
CD40 and CD86 by DCs. All of these functions were
ablated when STING-/- DCs were treated. We therefore
developed therapeutic regimens for in vivo studies using
pre-established B16.SIY melanoma tumors. Surprisingly,
a single intratumoral dose of DMXAA led to complete
elimination of tumors in the majority of mice. The endo-
genous T cell response against SIY, as assessed by IFN-b
ELISPOT and SIY/Kb pentamer FACS, was markedly
increased in animals treated with DMXAA. This thera-
peutic effect was eliminated in STING-/- hosts. Mice
with complete responses were completely protected
against rechallenge with B16.SIY, suggesting immunolo-
gic memory. Slightly inferior but similar anti-tumor
activity was observed with systemic (intraperitoneal)
administration of DMXAA. Our data suggest that
STING agonists can have profound therapeutic efficacy
through the activation of host DCs and augmented prim-
ing of endogenous anti-tumor T cells in vivo. Inasmuch
as DMXAA binds to murine but not human STING, the
development of analogs that similarly engage human
STING should receive high priority for ultimate clinical
translation.
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